Stopping means regain
- The withdrawal data
When treatment stops, the appetite biology reasserts itself. A year after stopping semaglutide, people regained about two-thirds of the lost weight (STEP 1 extension). In a tirzepatide withdrawal trial, those switched to placebo regained ~14% while those continuing kept losing; ~90% who continued held onto their loss vs ~17% who stopped. Blood pressure, glucose and lipid gains reverse in step. Evidence ●●●●●
- The framing
This behaves like blood-pressure or cholesterol medication: it works while taken, and the numbers drift back when it stops — not because the patient failed, but because the underlying drive was being suppressed, not removed. Current practice treats anti-obesity medication as indefinite therapy paired with the lifestyle foundation, not a time-limited course.